Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus weekly paclitaxel for platinum-resistant recurrent ovarian cancer
ChiCTR2100046031Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Zhengzhou University
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The Second Affiliated Hospital of Zhengzhou University. Primary endpoint: progression-free survival. Started May 2021; status: recruiting.
02
Drugs
anlotinibpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2100046031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046031.